Lineage Cell Therapeutics (LCTX) Shares Outstanding (2016 - 2025)
Historic Shares Outstanding for Lineage Cell Therapeutics (LCTX) over the last 13 years, with Q3 2025 value amounting to $230.3 million.
- Lineage Cell Therapeutics' Shares Outstanding rose 2197.19% to $230.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $230.3 million, marking a year-over-year increase of 2197.19%. This contributed to the annual value of $220.4 million for FY2024, which is 2596.14% up from last year.
- Per Lineage Cell Therapeutics' latest filing, its Shares Outstanding stood at $230.3 million for Q3 2025, which was up 2197.19% from $228.4 million recorded in Q2 2025.
- Over the past 5 years, Lineage Cell Therapeutics' Shares Outstanding peaked at $230.3 million during Q3 2025, and registered a low of $162.1 million during Q1 2021.
- Moreover, its 5-year median value for Shares Outstanding was $174.4 million (2023), whereas its average is $185.0 million.
- In the last 5 years, Lineage Cell Therapeutics' Shares Outstanding rose by 26.34% in 2023 and then skyrocketed by 2596.14% in 2024.
- Lineage Cell Therapeutics' Shares Outstanding (Quarter) stood at $169.5 million in 2021, then rose by 0.36% to $170.1 million in 2022, then grew by 2.88% to $175.0 million in 2023, then grew by 25.96% to $220.4 million in 2024, then increased by 4.5% to $230.3 million in 2025.
- Its Shares Outstanding was $230.3 million in Q3 2025, compared to $228.4 million in Q2 2025 and $228.4 million in Q1 2025.